UK – Sanofi’s Sarclisa bags NICE recommendation

French pharma Sanofi’s Sarclisa has been granted a positive recommendation from the National Institute for Health and Care (NICE) for patients with multiple myeloma.

Sarclisa (isatuximab) has been recommended in combination with pomalidomide and dexamethasone (pom-dex) for adult with relapsed/refractory multiple myeloma who have received three prior lines of treatment, and at least two prior therapies including lenalidomide and a proteasome inhibitor.

The recommendation was based on data from the ICARIA-MM trial, which demonstrated that Sarclisa plus pom-dex showed a reduction in risk of disease progression or death in adults by 40%…